+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Injection Pens Market - Forecasts from 2019 to 2024

  • ID: 4801682
  • Report
  • 105 pages
  • Knowledge Sourcing Intelligence LLP
UP TO OFF
until Dec 31st 2019
1 of 3

FEATURED COMPANIES

  • AstraZeneca
  • ELI Lilly and Company
  • Merck KGaA
  • Mylan Inc.
  • Novo Nordisk
  • Owen Mumford
  • MORE
The injection pens market is estimated to witness a CAGR of 7.62% to reach US$37.512 billion in 2024 from US$24.148 billion in 2018. Injection pens are infusion devices used to inject medications and offer easier administration of medication and are more accurate, and in a convenient way than the traditional vial and syringe method. They are portable and deliver accurate doses of insulin thus avoiding any wastage of the medication during the use. Injection pen is frequently used for self-administration of preserved multi-dose drug formulations requiring weight-based dosing. The increasing investments by companies for technological innovations for improving convenience and ease of administration of parenteral therapeutics is expected to drive the injection pens market. Furthermore, the rising prevalence of the chronic diseases such as diabetes, multiple sclerosis (MS), hemophilia and hemolytic diseases throughout the globe is also anticipated to boost the adoption of the injection pens, thus fueling the growth of the global injection pen market. However, low awareness regarding the injection pens and the presence of alternate modes of drug delivery might restrain the growth of the market during the given time frame.

The Injection pens market has been segmented on the basis of type, application, end user and geography. In the type segment, disposable injection pens are estimated to hold a significant market share owing to the low risk of infection when compared with reusable injection pens. In the application segment, diabetes is expected to drive the market growth owing to the increasing diabetic population across the globe. Geographically, North America is projected to be a dominant region on account of the rising number of diabetes cases coupled with the rising awareness in the region.

Drivers

Growing healthcare industry.

Rising number of chronic disease cases.

Restraints

Presence of alternative drug delivery systems.

Industry Update

In May 2018, Haselmeier, a Swiss-based developer and manufacturer of innovative self-injection devices, and Common Sensing, a Cambridge-based smart injector monitoring and support solutions company, today announced a partnership agreement to develop smart connected monitoring and support solutions for users of injectable medicines.

The major players profiled in the Injection Pens market include Novo Nordisk, Merck KGaA, Sanofi-Aventis US LLC, ELI Lilly and Company, Ypsomed AG, AstraZeneca, Owen Mumford, Pfizer, Wilhelm Haselmeier GmbH & Co. KG, Mylan Inc. and Becton, Dickinson and Company.

Segmentation

The Injection Pens market has been analyzed through the following segments:

By Type
Disposable pens
Reusable pens

By Application
Diabetes
Growth Hormone Therapy
Osteoporosis
Others

By End User
Hospitals and Clinics
Ambulatory Care
Home Care

By Geography
North America
USA
Canada
Mexico

South America
Brazil
Argentina
Others

Europe
Germany
France
United Kingdom
Spain
Others

Middle East and Africa
Saudi Arabia
Israel
Others

Asia Pacific
China
Japan
South Korea
India
Others
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AstraZeneca
  • ELI Lilly and Company
  • Merck KGaA
  • Mylan Inc.
  • Novo Nordisk
  • Owen Mumford
  • MORE
1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources

3. KEY FINDINGS

4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter's Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness

5. INJECTION PENS MARKET BY TYPE
5.1. Disposable pens
5.2. Reusable pens

6. INJECTION PENS MARKET BY APPLICATION
6.1. Diabetes
6.2. Growth Hormone Therapy
6.3. Osteoporosis
6.4. Others

7. INJECTION PENS MARKET BY END USER
7.1. Hospitals and Clinics
7.2. Ambulatory Care
7.3. Home Care

8. INJECTION PENS MARKET BY GEOGRAPHY
8.1. North America
8.1.1. USA
8.1.2. Canada
8.1.3. Mexico
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Others
8.3. Europe
8.3.1. Germany
8.3.2. France
8.3.3. United Kingdom
8.3.4. Spain
8.3.5. Others
8.4. Middle East and Africa
8.4.1. Saudi Arabia
8.4.2. Israel
8.4.3. Others
8.5. Asia Pacific
8.5.1. China
8.5.2. Japan
8.5.3. South Korea
8.5.4. India
8.5.5. Others

9. COMPETITIVE INTELLIGENCE
9.1. Competitive Benchmarking and Analysis
9.2. Recent Investments and Deals
9.3. Strategies of Key Players

10. COMPANY PROFILES
10.1. Novo Nordisk
10.2. Merck KGaA
10.3. Sanofi-Aventis US LLC
10.4. ELI Lilly and Company
10.5. Ypsomed AG
10.6. AstraZeneca
10.7. Owen Mumford
10.8. Pfizer
10.9. Wilhelm Haselmeier GmbH & Co. KG
10.10. Mylan Inc.
10.11. Becton, Dickinson and Company
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Novo Nordisk
  • Merck KGaA
  • Sanofi-Aventis US LLC
  • ELI Lilly and Company
  • Ypsomed AG
  • AstraZeneca
  • Owen Mumford
  • Pfizer
  • Wilhelm Haselmeier GmbH & Co. KG
  • Mylan Inc.
  • Becton, Dickinson and Company
Note: Product cover images may vary from those shown
Adroll
adroll